Lung Cancer Considered

By IASLCScience

Lung Cancer Considered episodes

July 21 Rewriting the Playbook: Cellular Therapy and Vaccines for ALK-Positive Lung Cancer
How could cellular therapies and cancer vaccines transform the future of treatment for ALK-positive lung cancer? Host Dr. Narjust Florez sits down with Dr. Vincent Lam and Dr. Carmen Mecca to explore the latest research, the science driving these innovative approaches, and what these advances could mean for patients and the future of precision oncology.
Key Topics Covered:
• ALK-positive lung cancer
• Cellular Therapy
• Vaccines
Guests:
Vincent Lam, MD
Associate Professor of Oncology, Johns Hopkins University School of Medicine
Director, Thoracic Oncology Clinical Research Program
Sidney Kimmel Comprehensive Cancer Center
Carmen Mecca. PhD
Postdoctoral Fellow, Chiarle Lab
Department of Pathology
Boston Children’s Hospital
48 min
July 07 IASLC - Your First Faculty Job
Starting your first faculty position can be both exciting and overwhelming. In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Dr. Arthi Sridhar to discuss the transition from fellowship to independent practice, sharing practical insights on navigating clinical responsibilities, building professional relationships, balancing personal and professional priorities, and developing a sustainable career in oncology. Whether you're beginning a career in academic or community practice, this conversation offers actionable advice to help you thrive in your early years as faculty.
Guests:
Arthi Sridhar, MD - [email protected]
Assistant Professor, Department of Internal Medicine
Harold C. Simmons Comprehensive Cancer Center
UT Southwestern Medical Center
42 min
June 23 Game Changers & Hard Truths: Dr. Balazs Halmos Unfiltered
In this episode of Lung Cancer Considered, Dr. Balazs Halmos reflects on a career at the forefront of thoracic oncology, sharing the pivotal moments, lessons learned, and hard truths that have shaped modern lung cancer care.
Guest:
Balazs Halmos, MD, MS
Professor of Medicine
Associate Director, Clinical Science
Montefiore Einstein Comprehensive Cancer Center
46 min
June 12 Welcome to Seoul: 2026 World Conference on Lung Cancer (WCLC) Preview
This episode of Lung Cancer Considered provide a preview of the upcoming IASLC 2026 World Conference on Lung Cancer in Seoul, South Korea this September. Key topics covered include
WCLC26 highlights - Multidisciplinary, WCLC26 deadlines and information about Seoul.
Guests:
Myung-Ju Ahn, MD, PhD
Distinguished Professor
Section of Hematology-Oncology, Department of Medicine
Hanyang University Medical Center, Hanyang University School of Medicine
Seoul, Republic of Korea
Vincent Wentao Fang, MD
Professor, Department of Thoracic Surgery
Shanghai East Hospital
Tongji University Medical School
Jiraporn Setakornnukul, MD, PhD
Radiation Oncologist, Associate Professor
Division of Radiation Oncology Department of Radiology
Faculty of Medicine, Siriraj Hospital Mahidol University
Bangkok, Thailand
Yasushi Yatabe, MD, PhD
Chief, Department of Diagnostic Pathology, National Cancer Center Hospital
Chief, Division of Molecular Pathology, National Cancer Center Research Institute
National Cancer Center Japan
40 min
June 09 ASCO 2026 Highlights – Part 2: Emerging Immunotherapy Strategies in Lung Cancer
In Part 2 of the ASCO 2026 Highlights series, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Julie Brahmer and Dr. Solange Peters to discuss some of the most notable immunotherapy advances presented at the 2026 ASCO Annual Meeting. The conversation explores emerging data for PD-1/VEGF and PD-L1/VEGF bispecific antibodies, the growing role of antibody-drug conjugates in combination with immunotherapy, and promising new strategies targeting KRAS-mutant lung cancers, highlighting how these approaches may reshape the future treatment landscape.
Guests:
Julie R. Brahmer, MD, MSc, FASCO, FAIO
The Marilyn Meyerhoff Professor of Thoracic Oncology
Co-Leader, Cancer Immunology Research Program
Co-Director, Upper Aerodigestive Cancers Program
Director, Johns Hopkins Kimmel Cancer Center, Bayview Campus
Professor Solange Peters, MD, PhD
Chair of Medical Oncology
Director of Oncology Department - CHUV
Lausanne University Hospital
41 min
June 05 ASCO 2026 Highlights – Part 1: Landmark Advances in Targeted Therapy
In this Part 1 of 2 ASCO 2026 Highlights episodes, hosts Dr. Narjust Florez and Dr. Stephen Liu are joined by Dr. Alice Shaw and Dr. Jonathan Goldman to review some of the most impactful targeted therapy data presented at the 2026 ASCO Annual Meeting. The discussion explores the practice-changing LIBRETTO-432 trial in early-stage RET-positive NSCLC, long-term outcomes with lorlatinib in ALK-positive disease, emerging data for neladalkib, and promising results for sunvozertinib in EGFR exon 20 insertion–positive NSCLC, highlighting how these findings may influence treatment decisions across disease stages.
Guests:
Dr. Alice Shaw. is a Professor of Medicine at Harvard Medical School, Chair of Medical Oncology, and a thoracic oncologist at Dana Farber Cancer Institute. She is widely recognized as a pioneer in the field of ALK-positive non-small cell lung cancer, having led landmark clinical trials that established crizotinib, ceritinib, and lorlatinib as standards of care.
Dr. Jonathan W. Goldman is a Professor of Medicine and thoracic oncologist at the UCLA David Geffen School of Medicine, where he serves as a principal investigator in the Phase I drug development program. Dr. Goldman has been at the forefront of early-phase oncology trials across multiple tumor types, with a particular focus on novel therapeutics in lung cancer, and he was the presenting author of Libretto 432 at the plenary session at the 2026 ASCO
46 min
May 19 Patients, AI, and Lung Cancer: Finding Clarity in the Noise
In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Natalie Brown and Dr. Aurora Lucas to explore how patients and caregivers are using artificial intelligence in the context of lung cancer care. The discussion highlights real-world experiences, addressing both the benefits of AI in improving understanding and empowerment, and the risks of misinformation, overreliance, and lack of personalization. The conversation also offers practical guidance for patients, families, and clinicians on using AI responsibly while reinforcing the importance of partnership with the care team.
Guests:
Aurora Lucas, EdD
Lung Cancer Patient Advocate
Natalie S. Brown, MBA
Lung Cancer Advocate & Speaker
Founder, Beyond The Diagnosis LLC
47 min
May 08 LCC in Italian: Resectable EGFR-mutant NSCLC
As part of IASLC’s ongoing series of podcasts in world languages, Dr. Alfredo Addeo moderates a Virtual Tumor Board discussion with Dr. Andrea Fillipi and Dr. Piergiorgio Solli. The tumor board focuses on the management of resectable EGFR-mutant NSCLC.
Host: • Alfredo Addeo, MD
Head of Oncology Service
University Hospital Geneva
Guests:
Andrea R. Filippi, MD
Head of Radiation Oncology, Fondazione Istituto Nazionale dei Tumori, Milan
Associate Professor, Radiation Therapy
Department of Oncology, University of Milan
Piergiorgio Solli, MD, PhD
Head of Thoracic Surgery
IRCCS Fondazione Istituto Nazionale dei Tumori, Milan
50 min
May 08 LCC Beyond Stage IV: Rethinking Oligometastatic Lung Cancer
This episode of Lung Cancer considered explores the evolving management of oligometastatic lung cancer. They break down key definitions, discuss when and how to use consolidative therapies like radiation and surgery, and examine patient selection, limitations, and emerging tools such as ctDNA that are shaping a more precise approach to care.
Guests:
Dr. Yasir Elamin is a thoracic/head and neck medical oncology fellowship director and associate professor in the department of thoracic/head and neck medical oncology at the University of Texas MD Anderson Cancer Center.
Dr. Lilian Faroni is a thoracic radiation oncologist atClínica São Vicente - Oncologia D'Orfrom Rio de Janeiro, Brazil. She specializes in the care of patients with oligometastatic lung cancer from oligopersistent to oligoprogressive disease.
48 min
May 05 AACR 2026 Highlights: KRAS Updates
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS updates from the American Association for Cancer Research (AACR) 2026 Annual Meeting with Dr. Deborah Doroshow, Dr. David S. Hong, and Dr. Jonathan Riess.
Guests:
Deborah Doroshow, MD, PhD
Associate Professor of Medicine, Hematology/Oncology
Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
David S. Hong, MD
Douglas E. Johnson Endowed Professor
Deputy Chair, Department of Investigational Cancer Therapeutics [A Phase I Program]
Division of Cancer Medicine
Clinical Medical Director, Clinical and Translational Research Center
The University of Texas MD Anderson Cancer Center
Jonathan Riess, MD
Associate Professor of Medicine, UC Davis Comprehensive Cancer Center
Director of Thoracic Oncology, University of California, Davis
47 min

About Lung Cancer Considered

From the publisher's feed

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.